CH617699A5 - - Google Patents
Download PDFInfo
- Publication number
- CH617699A5 CH617699A5 CH378079A CH378079A CH617699A5 CH 617699 A5 CH617699 A5 CH 617699A5 CH 378079 A CH378079 A CH 378079A CH 378079 A CH378079 A CH 378079A CH 617699 A5 CH617699 A5 CH 617699A5
- Authority
- CH
- Switzerland
- Prior art keywords
- formula
- pyrido
- group
- methyl
- dihydro
- Prior art date
Links
- -1 pyrrolidino, piperidino Chemical group 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- MGDDXKBVXQCWER-UHFFFAOYSA-N pyrido[2,3-i][1,2]benzodiazepin-3-one Chemical compound N1=NC(=O)C=CC2=CC=C(N=CC=C3)C3=C21 MGDDXKBVXQCWER-UHFFFAOYSA-N 0.000 claims description 7
- 208000006673 asthma Diseases 0.000 claims description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 5
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- ZUHZGEOKBKGPSW-UHFFFAOYSA-N tetraglyme Chemical compound COCCOCCOCCOCCOC ZUHZGEOKBKGPSW-UHFFFAOYSA-N 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 3
- 238000006114 decarboxylation reaction Methods 0.000 claims description 3
- 239000012442 inert solvent Substances 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims description 3
- 241000251730 Chondrichthyes Species 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- 150000007522 mineralic acids Chemical class 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 150000007524 organic acids Chemical class 0.000 claims 2
- 235000005985 organic acids Nutrition 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 claims 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims 1
- 150000008041 alkali metal carbonates Chemical class 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 claims 1
- 125000005270 trialkylamine group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 description 11
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 10
- 229960002657 orciprenaline Drugs 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 6
- 241000700199 Cavia porcellus Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- ACNTZJZMNCSWPV-UHFFFAOYSA-N Cl.O=C1N=C2C=CC=NC2=NC2=CC=CC=C12 Chemical compound Cl.O=C1N=C2C=CC=NC2=NC2=CC=CC=C12 ACNTZJZMNCSWPV-UHFFFAOYSA-N 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 230000007059 acute toxicity Effects 0.000 description 4
- 231100000403 acute toxicity Toxicity 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- NYZBHRWYUPFFJN-UHFFFAOYSA-N 1,2-benzodiazepin-5-one;hydrochloride Chemical compound Cl.O=C1C=CN=NC2=CC=CC=C12 NYZBHRWYUPFFJN-UHFFFAOYSA-N 0.000 description 3
- 208000009079 Bronchial Spasm Diseases 0.000 description 3
- 208000014181 Bronchial disease Diseases 0.000 description 3
- 206010006482 Bronchospasm Diseases 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001813 broncholytic effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- HCDXLUKTYFLIEM-UHFFFAOYSA-N 1,2-benzodiazepin-5-one Chemical compound O=C1C=CN=NC2=CC=CC=C12 HCDXLUKTYFLIEM-UHFFFAOYSA-N 0.000 description 2
- YZPAKBGVJIVPEU-UHFFFAOYSA-N 1,2-benzodiazepin-6-one Chemical compound N1=NC=CC=C2C(=O)C=CC=C21 YZPAKBGVJIVPEU-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000013213 extrapolation Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RELMFMZEBKVZJC-UHFFFAOYSA-N 1,2,3-trichlorobenzene Chemical compound ClC1=CC=CC(Cl)=C1Cl RELMFMZEBKVZJC-UHFFFAOYSA-N 0.000 description 1
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 1
- NKLSGXHBNYNNFA-UHFFFAOYSA-N 11-[2-[di(propan-2-yl)amino]ethyl]-5-methylpyrido[2,3-b][1,4]benzodiazepin-6-one;hydrochloride Chemical group Cl.O=C1N(C)C2=CC=CN=C2N(CCN(C(C)C)C(C)C)C2=CC=CC=C21 NKLSGXHBNYNNFA-UHFFFAOYSA-N 0.000 description 1
- SPPKYAJAQWPQHQ-UHFFFAOYSA-N 11-[2-[di(propan-2-yl)amino]ethyl]-6-methylpyrido[3,2-c][1,5]benzodiazepin-5-one;hydrochloride Chemical compound Cl.CN1C(=O)C2=CC=CN=C2N(CCN(C(C)C)C(C)C)C2=CC=CC=C21 SPPKYAJAQWPQHQ-UHFFFAOYSA-N 0.000 description 1
- XCJRFCBWBSNFHN-UHFFFAOYSA-N 11-[3-(dipropylamino)propyl]-6-methylpyrido[3,2-c][1,5]benzodiazepin-5-one;hydrochloride Chemical compound Cl.CN1C(=O)C2=CC=CN=C2N(CCCN(CCC)CCC)C2=CC=CC=C21 XCJRFCBWBSNFHN-UHFFFAOYSA-N 0.000 description 1
- RZKKHOWMPKVNBG-UHFFFAOYSA-N 11-[3-[di(propan-2-yl)amino]propyl]-5-methylpyrido[2,3-b][1,4]benzodiazepin-6-one;hydrochloride Chemical group Cl.O=C1N(C)C2=CC=CN=C2N(CCCN(C(C)C)C(C)C)C2=CC=CC=C21 RZKKHOWMPKVNBG-UHFFFAOYSA-N 0.000 description 1
- SFRAVXBSPHJEBZ-UHFFFAOYSA-N 6,11-dihydropyrido[3,2-c][1,5]benzodiazepin-5-one Chemical compound O=C1NC2=CC=CC=C2NC2=NC=CC=C12 SFRAVXBSPHJEBZ-UHFFFAOYSA-N 0.000 description 1
- JIGPZVICWWQITP-UHFFFAOYSA-N 6-methyl-11-(2-pyrrolidin-1-ylethyl)pyrido[3,2-c][1,5]benzodiazepin-5-one;hydrochloride Chemical compound Cl.C12=NC=CC=C2C(=O)N(C)C2=CC=CC=C2N1CCN1CCCC1 JIGPZVICWWQITP-UHFFFAOYSA-N 0.000 description 1
- ONUDKSCEPDVUPP-UHFFFAOYSA-N 6-methyl-11h-pyrido[3,2-c][1,5]benzodiazepin-5-one Chemical compound O=C1N(C)C2=CC=CC=C2NC2=NC=CC=C21 ONUDKSCEPDVUPP-UHFFFAOYSA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- FTLLYQBNLRSNRN-UHFFFAOYSA-N CN1C2=C(N=CC=C2)N(C3=CC=CC=C3C1=O)C(=O)OCCN(C)C Chemical compound CN1C2=C(N=CC=C2)N(C3=CC=CC=C3C1=O)C(=O)OCCN(C)C FTLLYQBNLRSNRN-UHFFFAOYSA-N 0.000 description 1
- OZNIZUUWTHZLIW-UHFFFAOYSA-N Cl.CC=1C=CC=2C(=NC3=C(C(N2)=O)C=CC=C3)N1 Chemical compound Cl.CC=1C=CC=2C(=NC3=C(C(N2)=O)C=CC=C3)N1 OZNIZUUWTHZLIW-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 101000952234 Homo sapiens Sphingolipid delta(4)-desaturase DES1 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 102100037416 Sphingolipid delta(4)-desaturase DES1 Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
- 229950009941 chloralose Drugs 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 206010028320 muscle necrosis Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2424811A DE2424811C3 (de) | 1974-05-22 | 1974-05-22 | Pyrido-benzodiazepinone, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH617699A5 true CH617699A5 (en, 2012) | 1980-06-13 |
Family
ID=5916217
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH641375A CH617694A5 (en, 2012) | 1974-05-22 | 1975-05-20 | |
| CH377979A CH617698A5 (en, 2012) | 1974-05-22 | 1979-04-20 | |
| CH378079A CH617699A5 (en, 2012) | 1974-05-22 | 1979-04-20 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH641375A CH617694A5 (en, 2012) | 1974-05-22 | 1975-05-20 | |
| CH377979A CH617698A5 (en, 2012) | 1974-05-22 | 1979-04-20 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US4021557A (en, 2012) |
| JP (1) | JPS5224038B2 (en, 2012) |
| AT (1) | AT342058B (en, 2012) |
| BE (1) | BE829327A (en, 2012) |
| BG (3) | BG23901A3 (en, 2012) |
| CH (3) | CH617694A5 (en, 2012) |
| CS (1) | CS191264B2 (en, 2012) |
| DD (1) | DD117459A5 (en, 2012) |
| DE (1) | DE2424811C3 (en, 2012) |
| DK (1) | DK139724C (en, 2012) |
| ES (3) | ES437423A1 (en, 2012) |
| FI (1) | FI57259C (en, 2012) |
| FR (1) | FR2271831B1 (en, 2012) |
| GB (1) | GB1456627A (en, 2012) |
| HU (1) | HU173786B (en, 2012) |
| IE (1) | IE41244B1 (en, 2012) |
| IL (1) | IL47329A (en, 2012) |
| LU (1) | LU72560A1 (en, 2012) |
| NL (1) | NL7506008A (en, 2012) |
| NO (1) | NO141894C (en, 2012) |
| PH (1) | PH13405A (en, 2012) |
| PL (3) | PL98951B1 (en, 2012) |
| RO (2) | RO66914A (en, 2012) |
| SE (1) | SE421921B (en, 2012) |
| SU (3) | SU578878A3 (en, 2012) |
| YU (1) | YU130775A (en, 2012) |
| ZA (1) | ZA753272B (en, 2012) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2644121A1 (de) * | 1976-09-30 | 1978-04-06 | Thomae Gmbh Dr K | Neue pyridobenzodiazepinone, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
| EP0024582A1 (de) * | 1979-08-10 | 1981-03-11 | Byk Gulden Lomberg Chemische Fabrik GmbH | Benzodiazepinone, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel |
| IL62792A (en) * | 1980-05-07 | 1985-02-28 | Byk Gulden Lomberg Chem Fab | Acylated dihydrothienodiazepinone compounds,process for their preparation,and medicaments containing them |
| US4381301A (en) * | 1980-05-07 | 1983-04-26 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Substituted tricyclic thieno compounds, their synthesis, their use, their compositions and their medicaments |
| SE448629B (sv) * | 1981-09-24 | 1987-03-09 | Robins Co Inc A H | Pyrido/1,4/bensodiazepiner |
| GB2110205B (en) * | 1981-09-24 | 1985-10-23 | Robins Co Inc A H | Methanone compounds and their use in the production of phenyl substituted pyrido]1,4 benzediazepiness |
| DE3643666A1 (de) * | 1986-12-20 | 1988-06-30 | Thomae Gmbh Dr K | Neue kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| ATE161535T1 (de) * | 1989-04-20 | 1998-01-15 | Boehringer Ingelheim Pharma | 6,11-dihydro-5h-pyrido(2,3-b)(1,5)benzodiazepin 5-one und thione und ihre verwendung für die vorbeugung oder behandlung von aids |
| CA2052946A1 (en) * | 1990-10-19 | 1992-04-20 | Karl G. Grozinger | Method for the preparation of 5,11-dihydro-6h-dipyrido ¬3,2-b:2', 3'-e| ¬1,4|diazepines |
| FR2850654A1 (fr) * | 2003-02-03 | 2004-08-06 | Servier Lab | Nouveaux derives d'azepines tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP5020819B2 (ja) | 2004-07-16 | 2012-09-05 | プロテオシス・アーゲー | 細胞保護剤としての、ｐａｒｐ及びｓｉｒ調節活性を有するムスカリンアンタゴニスト |
| WO2010081825A2 (en) | 2009-01-13 | 2010-07-22 | Proteosys Ag | Pirenzepine as an agent in cancer treatment |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3316249A (en) * | 1967-04-25 | Part a.xmethyl n n-(z-diethylaminoethyl)-n-(z- nitrophenyl) anthranilate hydrochloride | ||
| FR1505795A (fr) * | 1965-12-17 | 1967-12-15 | Thomae Gmbh Dr K | Procédé pour fabriquer de nouvelles 11h-pyrido[2, 3-b][1, 5]benzodiazépine-5(6h)-ones substituées en position 11 |
| DE1795183B1 (de) * | 1968-08-20 | 1972-07-20 | Thomae Gmbh Dr K | 5,11-Dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-on-derivate und Arzneimittel |
| FI49509C (fi) * | 1968-08-20 | 1975-07-10 | Thomae Gmbh Dr K | Menetelmä farmakologisesti vaikuttavien 5-asemaan substituoitujen 5,10 -dihydro-11H-dibentso/b,e//1,4/deatsepiini-11-onien ja niiden suolojen valmistamiseksi. |
| AT327200B (de) * | 1972-09-06 | 1976-01-26 | Degussa | Verfahren zur herstellung von neuen aza-10,11-dihydro-5h-dibenzo (b,e)-(1,4) diazepinen sowie deren salzen |
-
1974
- 1974-05-22 DE DE2424811A patent/DE2424811C3/de not_active Expired
-
1975
- 1975-04-09 AT AT267475A patent/AT342058B/de not_active IP Right Cessation
- 1975-04-23 US US05/570,805 patent/US4021557A/en not_active Expired - Lifetime
- 1975-04-25 PH PH17099A patent/PH13405A/en unknown
- 1975-05-03 ES ES437423A patent/ES437423A1/es not_active Expired
- 1975-05-15 SU SU7502133310A patent/SU578878A3/ru active
- 1975-05-20 BG BG030870A patent/BG23901A3/xx unknown
- 1975-05-20 CH CH641375A patent/CH617694A5/de not_active IP Right Cessation
- 1975-05-20 BG BG030032A patent/BG23541A3/xx unknown
- 1975-05-20 DD DD186145A patent/DD117459A5/xx unknown
- 1975-05-20 HU HU75TO1004A patent/HU173786B/hu unknown
- 1975-05-20 FI FI751470A patent/FI57259C/fi not_active IP Right Cessation
- 1975-05-20 BG BG030869A patent/BG24807A3/xx unknown
- 1975-05-21 CS CS753556A patent/CS191264B2/cs unknown
- 1975-05-21 PL PL1975180585A patent/PL98951B1/pl unknown
- 1975-05-21 PL PL1975193638A patent/PL98614B1/pl unknown
- 1975-05-21 BE BE156569A patent/BE829327A/xx unknown
- 1975-05-21 ZA ZA3272A patent/ZA753272B/xx unknown
- 1975-05-21 DK DK223175A patent/DK139724C/da not_active IP Right Cessation
- 1975-05-21 GB GB2198575A patent/GB1456627A/en not_active Expired
- 1975-05-21 NO NO751801A patent/NO141894C/no unknown
- 1975-05-21 JP JP50060889A patent/JPS5224038B2/ja not_active Expired
- 1975-05-21 YU YU01307/75A patent/YU130775A/xx unknown
- 1975-05-21 RO RO7582297A patent/RO66914A/ro unknown
- 1975-05-21 SE SE7505796A patent/SE421921B/xx unknown
- 1975-05-21 RO RO7591013A patent/RO71575A/ro unknown
- 1975-05-21 PL PL1975193639A patent/PL100079B1/pl unknown
- 1975-05-21 IL IL47329A patent/IL47329A/xx unknown
- 1975-05-22 IE IE1146/75A patent/IE41244B1/xx unknown
- 1975-05-22 LU LU72560A patent/LU72560A1/xx unknown
- 1975-05-22 FR FR7515960A patent/FR2271831B1/fr not_active Expired
- 1975-05-22 NL NL7506008A patent/NL7506008A/xx not_active Application Discontinuation
- 1975-10-08 ES ES441591A patent/ES441591A1/es not_active Expired
- 1975-10-08 ES ES441592A patent/ES441592A1/es not_active Expired
-
1976
- 1976-03-11 SU SU7602331204A patent/SU567407A3/ru active
- 1976-03-11 SU SU762331952A patent/SU587864A3/ru active
-
1979
- 1979-04-20 CH CH377979A patent/CH617698A5/de not_active IP Right Cessation
- 1979-04-20 CH CH378079A patent/CH617699A5/de not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2901181C2 (de) | N-(1-Alkyl- bzw. Allyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-alkylsulfonylbenzamide, deren Salze, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
| DE2356900A1 (de) | Substituierte chromon-3-carbonitrile, -carboxamide und -carbonsaeuren, deren salze und diese verbindungen enthaltende arzneimittel | |
| CH617699A5 (en, 2012) | ||
| DE2855064C2 (de) | 2-Aminomethyl-6-jodphenol-Derivate und Verfahren zu deren Herstellung | |
| DE1695111B1 (de) | Indolderivate | |
| EP0576906A1 (de) | Neue Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Antiinflammatorium und Analgeticum | |
| DE1470139C3 (de) | 5,11-Dihydrodibenz eckige Klammer auf b,e eckige Klammer zu-1,4-oxazepine und Verfahren zu ihrer Herstellung | |
| CH653032A5 (de) | Bicyclische verbindungen, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel. | |
| CH637957A5 (de) | Verfahren zur herstellung neuer pyridobenzodiazepinone und ihrer salze. | |
| DE2431292A1 (de) | Neue carbazol-derivate | |
| DE2259471C2 (de) | 2-Halogen-9-phenyl-5,6-dihydro-7H-pyrido [2,3-f] [1,4] diazepinderivate | |
| CH461489A (de) | Verfahren zur Herstellung von neuen Oxazolderivaten | |
| CH658656A5 (de) | Neue eburnamenin-14-carbonsaeure-derivate, verfahren zu ihrer herstellung und die neuen verbindungen enthaltende arzneimittelpraeparate. | |
| CH513806A (de) | Verfahren zur Herstellung von tricyclischen Verbindungen | |
| DE2308064C3 (de) | Benzotriazole, ihre Salze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| AT355581B (de) | Verfahren zur herstellung neuer pyrido- benzodiazepinone und ihrer salze | |
| DE2300367A1 (de) | Alkenyl- und alkinylsubstituierte xanthoncarbonsaeuren | |
| AT347423B (de) | Verfahren zur herstellung von neuen 7- aminobenzocycloheptenen und von deren salzen | |
| CH643845A5 (de) | Pyrido(2,3-e)-as-triazin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate. | |
| CH635100A5 (en) | Process for the preparation of novel pyrido[1,2-a]pyrimidine derivatives | |
| DE1936670C3 (de) | S-Diallylaminoalkanoyl-SJO-dihydro-11H-dibenzo eckige Klammer auf b,e eckige Klammer zu- eckige Klammer auf 1,4 eckige Klammer zu diazepin-11-onderivate | |
| DE2433837B2 (de) | 1-Amidino-3-phenyl-harnstoffe, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende therapeutische Zubereitungen | |
| AT300797B (de) | Verfahren zur Herstellung von neuen Benzodipyronen | |
| DE1931487B2 (de) | In 5-Stellung substituierte 5,10-Dihydro-11 H-dibenzo eckige Klammer auf b,e eckige Klammer zu eckige Klammer auf 1,4 eckige Klammer zu diazepin-11-one und Verfahren zu ihrer Herstellung | |
| DE2813895A1 (de) | Neue 2,4,6-trisubstituierte 2,3- dihydrobenzofuranderivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |